Salus BioMed secures tens of millions in Series B1 funding from AmoyDx to forge strategic partnership in precision oncology

Recently, Salus BioMed announced the completion of its Series B1 financing round, raising tens of millions of yuan. The investment came from AmoyDx (Stock Code: 300685), a listed company in China's precision oncology diagnostics sector. This collaboration will fully leverage Salus BioMed's core strengths in sequencing platforms, effectively complementing AmoyDx's technological expertise and product capabilities in tumor gene testing. The raised funds will support the registration and application processes for the domestically developed sequencing platform, capacity expansion, and global market development.

As an innovative enterprise focused on cutting-edge technology R&D, Salus BioMed is committed to developing and optimizing upstream sequencing platforms with independent intellectual property rights, super-resolution spatial omics platforms, and solid-phase gene chip testing platforms. The company's self-developed technology system demonstrates unique advantages in precision oncology diagnosis, treatment, and drug development. Amid the long-term dominance of imported sequencing equipment in the Chinese market, Salus BioMed has broken through technological barriers with its independently developed Salus Pro sequencer. In January 2025, the device obtained Class II medical device registration from China's National Medical Products Administration (NMPA), becoming the first sequencing platform using reversible terminator technology in China to receive approval for comprehensive clinical applications. It is clinically used for sequencing DNA and RNA derived from human samples, featuring flexible and adjustable throughput, with costs reduced by 40% compared to imported equipment. Currently, Salus Pro has been adopted by nearly 100 hospitals and third-party laboratories, and has received EU CE-IVDR certification, as well as medical device licenses in Thailand and Indonesia, with products exported to markets in Europe, North America, and Southeast Asia.

As a leader in China's precision oncology medicine sector, AmoyDx's investment in Salus BioMed reflects its strong recognition of the company's technological innovation and development potential. This move also underscores industry recognition of the synergistic value between sequencing technology and clinical needs. With a sales network covering over 500 tertiary hospitals in China and more than 60 countries and regions worldwide, AmoyDx holds 32 Class III medical device registrations and has secured approval for two NGS innovative medical devices. Its tumor companion diagnostic products, including ROS1, PCR 11-gene, and FGFR2, have been approved in markets such as Japan and incorporated into local healthcare insurance systems. The collaboration is expected to accelerate the translation of sequencing technology from research to clinical practice.

The completion of this financing round marks a new phase in the collaboration between AmoyDx and Salus BioMed. It not only opens new opportunities for in-depth synergy in technology, market presence, and industrial resources, but also advances the large-scale clinical adoption and global expansion of China's domestically developed high-end sequencing platforms. With continuous technological breakthroughs and deeper clinical integration, the partnership between AmoyDx and Salus BioMed is poised to bring new momentum to the development of precision oncology diagnosis and treatment systems in China and beyond, ushering in a new era of more efficient and accessible precision medicine.